Nature Search

Erythrocyte–antibody conjugates to overcome immunotherapy resistance

Strategies are needed to overcome resistance to immune checkpoint inhibitors in patients with cancer. An erythrocyte–antibody conjugate for the delivery of anti-PD-1 is now shown to favorably reshape anti-tumor immune responses, with promising safety and efficacy data from a phase 1 trial in patients with advanced anti-PD-1-resistant solid tumors.

Urvashi Mitbander Joshi
Rodabe N. Amaria
News & Views20 Feb 2026
Nature Cancer

P: 1-3
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

A pooled analysis of neoadjuvant immunotherapy trials in melanoma shows that the degree of pathological response associates with patient survival and might represent a surrogate marker for long-term outcomes.

Alexander M. Menzies
Rodabe N. Amaria
Georgina V. Long
Research08 Feb 2021
Nature Medicine

Volume: 27, P: 301-309
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Rodabe N. Amaria
Michael Postow
Hussein A. Tawbi
Amendments and CorrectionsOpen Access09 Mar 2023
Nature

Volume: 615, P: E23
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria
Sangeetha M. Reddy
Jennifer A. Wargo
Amendments and Corrections25 Oct 2018
Nature Medicine

Volume: 24, P: 1942
Neoadjuvant relatlimab and nivolumab in resectable melanoma

Patients with resectable clinical stage III or oligometastatic stage IV melanoma were given neoadjuvant relatlimab and nivolumab combination immunotherapy, which induced a high pathologic complete response rate, indicating the efficacy and safety of this regimen.

Rodabe N. Amaria
Michael Postow
Hussein A. Tawbi
ResearchOpen Access26 Oct 2022
Nature

Volume: 611, P: 155-160
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria
Sangeetha M. Reddy
Jennifer A. Wargo
Amendments and Corrections25 Oct 2018
Nature Medicine

Volume: 24, P: 1941
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

In the randomized phase 1b/2 Morpheus-Melanoma trial evaluating various neoadjuvant immune checkpoint inhibitor regimens in patients with resectable stage III melanoma, tobemstomig, an anti-PD-1/anti-LAG-3 bispecific antibody, showed the highest pathologic response rate with a better safety profile than the standard treatment approach of ipilimumab plus nivolumab.

Georgina V. Long
Nitya Nair
Christian Blank
ResearchOpen Access24 Sept 2025
Nature Medicine

Volume: 31, P: 3700-3712
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.

Rodabe N. Amaria
Sangeetha M. Reddy
Jennifer A. Wargo
Research08 Oct 2018
Nature Medicine

Volume: 24, P: 1649-1654
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Isabella C. Glitza Oliva
Sherise D. Ferguson
Michael A. Davies
Amendments and CorrectionsOpen Access22 Apr 2024
Nature Medicine

Volume: 30, P: 1787
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

In an interim analysis of a phase 1 trial of concurrent intrathecal and intravenous anti-PD1 delivery in patients with leptomeningeal disease and melanoma, treatment was feasible and well-tolerated with no dose-limiting toxicities.

Isabella C. Glitza Oliva
Sherise D. Ferguson
Michael A. Davies
ResearchOpen Access30 Mar 2023
Nature Medicine

Volume: 29, P: 898-905
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Treatment with neoadjuvant BRAF/MEK-targeted therapy results in higher rates of major pathological response in female compared with male patients with melanoma, and pharmacological inhibition of androgen receptor signalling improved the responses of male and female mice to BRAF/MEK-targeted therapy.

Christopher P. Vellano
Michael G. White
Jennifer A. Wargo
Research15 Jun 2022
Nature

Volume: 606, P: 797-803
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Christopher P. Vellano
Michael G. White
Jennifer A. Wargo
Amendments and Corrections10 Jan 2023
Nature

Volume: 613, P: E3
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Clinical benefit or intestinal toxicity resulting from combined immune checkpoint blockade in patients with melanoma associates with prevalent commensal bacteria and can be decoupled by IL-1R inhibition.

Miles C. Andrews
Connie P. M. Duong
Jennifer A. Wargo
Research08 Jul 2021
Nature Medicine

Volume: 27, P: 1432-1441
B cells and tertiary lymphoid structures promote immunotherapy response

Multiomic profiling of several cohorts of patients treated with immune checkpoint blockade highlights the presence and potential role of B cells and tertiary lymphoid structures in promoting therapy response.

Beth A. Helmink
Sangeetha M. Reddy
Jennifer A. Wargo
Research15 Jan 2020
Nature

Volume: 577, P: 549-555
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.

Claus Garbe
Reinhard Dummer
Georgina V. Long
Comments & Opinion16 May 2023
Nature Medicine

Volume: 29, P: 1310-1312
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy.

Rina M. Mbofung
Jodi A. McKenzie
Patrick Hwu
ResearchOpen Access06 Sept 2017
Nature Communications

Volume: 8, P: 1-8
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

Alexandre Reuben
Christine N. Spencer
Jennifer A. Wargo
ResearchOpen Access07 Apr 2017
npj Genomic Medicine

Volume: 2, P: 1-11

Search

Filter By:

Search

Quick links